Most top pharma companies derive more than 60 percent of their revenue from therapies for diseases that affect women uniquely, differently, or disproportionately, putting them in a prime position to close the sex- and gender-based health gap.
Source: McKinsey

Closing the women’s health gap: Biopharma’s untapped opportunity